Abstract: Objective：To investigate the diagnostic value of seven tumourassociated autoantibodies, including p53, PGP9.5, SOX2, GAGE7, GBU4-5, MAGE A1 and CAGE autoantibodies, in the newly diagnosed patients with lung cancer. Methods：A total of 108 patients with newly diagnosed lung cancer, 120 with benign lung diseases, 227 with other cancers and 96 healthy controls were enrolled in the study. Their serum levels of seven autoantibodies were detected by enzyme linked immunosorbent assay (ELISA). The ROC curve was drawn and used to analyze their diagnostic efficiency for lung cancer. The diagnostic value of the combination of seven autoantibodies in different groups was also compared. Results：The serum levels of seven autoantibodies in lung cancer patients were significantly higher than those in the patients with benign lung diseases or other cancers and healthy controls (P＜0.05). The sensitivity, specificity and AUC^ROC of the combination of seven autoantibodies in the preliminary diagnosis of lung cancer were 62.00%, 89.80% and 0.769, respectively, and its sensitivity and AUC^ROC were higher than those of single autoantibody. The positive rate of the combination of seven autoantibodies in lung cancer patients was significantly higher than those in healthy controls (χ²=50.885, P＜0.01) and the patients with benign lung diseases (χ²=56.341,P＜0.01) or other cancers (χ²=46.812, P＜0.01). Conclusion: The combination detection of seven autoantibodies, including p53, PGP9.5, SOX2, GAGE7, GBU4-5, MAGE A1 and CAGE, may serve as potential markers for the diagnosis of lung cancer.